Not currently recruiting at UCSF
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
a study on Neoplasm
Neoplasm Advanced cancer solid tumors PI3K mTOR PI3K/mTOR metastatic Triple Negative Breast Cancer (TNBC) Triple Negative Breast Neoplasms Docetaxel Cisplatin Antineoplastic Agents PF-05212384 (gedatolisib) Dacomitinib
Lead Scientist at UCSF
- Hope Rugo
Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer.
- accepting new patients
- Start Date
- Completion Date
- To obtain contact information for a study center near you, click here.
- Phase 1
- Study Type
- Last Updated